奥贝胆酸治疗原发性胆汁性胆管炎的长期安全性与疗效:POISE长期安全性扩展研究最终结果
POISE开放标签扩展研究(N=193)评估奥贝胆酸治疗对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者的长期安全性与疗效。数据截尾至奥贝胆酸滴定>10 mg后,最常见治疗中出现的不良事件为瘙痒(70%),严重肝脏相关不良事件5例(3%),研究者评估与奥贝胆酸无关。肝脏生化指标持续改善,第72个月POISE主要终点应答率为63%,肝脏硬度稳定。
要点
- 奥贝胆酸长期治疗PBC患者耐受性总体可控,最常见不良事件为瘙痒(70%)。
- 严重肝脏相关不良事件5例(3%),研究者评估与奥贝胆酸无关。
- 第72个月POISE主要终点应答率63%,肝脏硬度稳定。
核心结论
- POISE开放标签扩展研究最终结果支持奥贝胆酸长期治疗对UDCA应答不佳或不耐受的PBC患者具有安全性和疗效。
- 研究达到持续疗效且无意外安全性发现的研究目标后终止。
研究设计与样本
- POISE 3期双盲试验的开放标签扩展研究,所有进入扩展期的患者(N=193)起始奥贝胆酸5 mg每日一次,至少3个月后可增加剂量。
- 安全性及疗效在总体扩展期人群中评估,额外分析对奥贝胆酸滴定>10 mg后的数据点进行截尾以与处方标签一致。
主要发现
- 数据截尾至奥贝胆酸滴定>10 mg后,最常见治疗中出现的不良事件为瘙痒(70%)。
- 严重肝脏相关治疗中出现的不良事件报告于5例患者(3%),严重肝脏相关不良事件及死亡(n=2,1%)经研究者评估与奥贝胆酸无关。
- 整个扩展期内肝脏生化指标改善,第72个月POISE主要终点应答率为63%。
- 经瞬时弹性成像测量的肝脏硬度在研究期间保持稳定。
关键数值与推荐
- 第72个月POISE主要终点应答率为63%。
- 瘙痒发生率70%,严重肝脏相关治疗中出现的不良事件5例(3%)。
- 死亡n=2(1%),研究者评估与奥贝胆酸无关。
临床怎么用
- 对于UDCA应答不佳或不耐受的PBC患者,长期奥贝胆酸治疗可维持生化应答且肝脏硬度稳定。
- 临床需关注瘙痒等不良事件,严重肝脏相关事件经评估与奥贝胆酸无关。
局限性
- 原文摘要未报告对照组的长期比较数据。
- 部分分析对奥贝胆酸滴定>10 mg后的数据点进行截尾,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obeticholic acid (OCA) has been evaluated in patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA) in the 12-month, double-blind, phase 3 POISE trial. A 3-year interim analysis of the open-label extension (OLE) demonstrated a favourable safety profile with sustained improvements in liver biochemistries. AIM: To present the final long-term safety and efficacy data from the 5-year POISE OLE. METHODS: All patients who entered the OLE (N = 193) were started on OCA 5 mg daily for a minimum of 3 months, after which the dose could be increased. Safety and efficacy were evaluated in the overall OLE population. Additional analyses censored data points following OCA titration > 10 mg to align with the prescribing label. RESULTS: POISE was terminated after it was determined that the OLE had achieved its study objectives of sustained efficacy with no unexpected safety findings. With censoring of data points following OCA titration to > 10 mg, the most common treatment-emergent adverse event (TEAE) was pruritus (70%); serious hepatic-related TEAEs were reported in five patients (3%). The serious hepatic-related TEAEs and deaths (n = 2, 1%) were assessed by the Investigators as unrelated to OCA. Liver biochemistries improved throughout the OLE; the response rate for the POISE primary endpoint was 63% at Month 72. Liver stiffness, as measured by transient elastography, was stable over the study duration. CONCLUSIONS: Findings from the POISE OLE support the safety and efficacy profile of long-term OCA treatment for patients with PBC with inadequate response or intolerance to UDCA (NCT01473524). TRIAL REGISTRATION: Phase 3 study of obeticholic acid in patients with primary biliary cirrhosis (POISE) ClinicalTrials.gov identifier: NCT01473524.
引用
- Bowlus CL, Nevens F, Kowdley KV, et al. Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension. Aliment Pharmacol Ther. 2026. PMID: 42449190. doi:10.1111/apt.70832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。